Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate

Higaki, Megumu; Ishihara, Tsutomu; Izumo, Nobuo; Takatsu, Mitsuharu; Mizushima, Yutaka

doi:10.1136/ard.2004.030759

Cited by 132 publications

(70 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[45][46][47][48][49][50][51][52][53] Higaki et al demonstrated that the continuous administration of betamethasone sodium phosphate through PLGA nanoparticles provided increased inhibition of inflammation in an experimental model of OA when compared with the same dosage of betamethasone sodium phosphate delivered three times through IA injection. 54 Dang et al demonstrated that dex releasing PLGA microparticles are capable of suppressing the host response to implanted polymer materials in a mouse model. Notably, animals that received a higher drug loading treatment suffered an increased incidence of death within 7-10 days after administration, while a low drug loading group maintained healthy body conditions, but still benefited from the drug's anti-inflammatory properties.…”

Section: Introductionmentioning

confidence: 99%

Dexamethasone Release from Within Engineered Cartilage as a Chondroprotective Strategy Against Interleukin-1α

RoachBrendan

Kelmendi-DokoArta

BalutisElaine

et al. 2016

Tissue Engineering Part A

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Dexamethasone Release from Within Engineered Cartilage as a Chondroprotective Strategy Against Interleukin-1α

RoachBrendan

Kelmendi-DokoArta

BalutisElaine

et al. 2016

Tissue Engineering Part A

View full text Add to dashboard Cite

“…Arthritis was induced using the reported methods (Terato et al, 1995;Higaki et al, 2005). BALB/c mice were injected intravenously with 2 mg/kg of an arthritogenic monoclonal antibody cocktail (Chondrex, LLC, Seattle, WA) on day Ϫ5, and lipopolysaccharide (LPS; 2.5 mg/ kg) was injected intraperitoneally on day Ϫ2.…”

Section: Methodsmentioning

confidence: 99%

Treatment of Experimental Arthritis with Stealth-Type Polymeric Nanoparticles Encapsulating Betamethasone Phosphate

Ishihara¹,

Kubota²,

Choi³

et al. 2009

J Pharmacol Exp Ther

View full text Add to dashboard Cite

We examined the therapeutic activity of betamethasone disodium 21-phosphate (BP) encapsulated in biocompatible and biodegradable blended nanoparticles of poly (D,L-lactic/glycolic acid) (PLGA)/poly(D,L-lactic acid) (PLA) homopolymers and polyethylene glycol (PEG)-block-PLGA/PLA copolymers (stealth nanosteroid) in experimental arthritis models. Various stealth nanosteroids with a size of 45 to 115 nm were prepared and then intravenously administered to rats with adjuvant arthritis (AA) rats and mice with anti-type II collagen antibody-induced arthritis (AbIA). The accumulation of stealth nanoparticles with Cy7 in inflamed joints was determined using an in vivo imaging system. The type A stealth nanosteroid, composed of PLA (2.6 kDa) and PEG (5 kDa)-PLA (3 kDa), with a PEG content of 10% and a diameter of 115 nm, exhibited the highest anti-inflammatory activity. In AA rats, a 35% decrease in paw inflammation was obtained in 1 day and maintained for 9 days with a single injection of the type A stealth nanosteroid (40 g of BP), whereas the same does of nonstealth nanosteroid and 3 times higher free BP showed a significantly weaker response.

show abstract

“…[7][8][9] Among the different polymers developed for biomedical applications, PLGA has attracted considerable attention due to its interesting properties: 10 1) predictable biodegradability and biocompatibility, 2) US Food and Drug Administration and European Medicine Agency approvals for its drug delivery systems intended for parenteral administration, 3) welldescribed formulations and methods of production adapted to the encapsulation of various types of hydrophilic or hydrophobic active pharmaceutical ingredients, 4) drug protection from biochemical degradation, 5) possibility to target its based nanoparticles (NPs) to specific tissues or cells, 6) possibility of sustained release, and 7) possibility to easily modify its surface properties.…”

Section: Introductionmentioning

confidence: 99%

Continuous synthesis of drug-loaded nanoparticles using microchannel emulsification and numerical modeling: effect of passive mixing

Solorzano¹,

Usón²,

Larrea³

et al. 2016

IJN

View full text Add to dashboard Cite

By using interdigital microfluidic reactors, monodisperse poly( d , l lactic-co-glycolic acid) nanoparticles (NPs) can be produced in a continuous manner and at a large scale (~10 g/h). An optimized synthesis protocol was obtained by selecting the appropriated passive mixer and fluid flow conditions to produce monodisperse NPs. A reduced NP polydispersity was obtained when using the microfluidic platform compared with the one obtained with NPs produced in a conventional discontinuous batch reactor. Cyclosporin, an immunosuppressant drug, was used as a model to validate the efficiency of the microfluidic platform to produce drug-loaded monodisperse poly( d , l lactic-co-glycolic acid) NPs. The influence of the mixer geometries and temperatures were analyzed, and the experimental results were corroborated by using computational fluid dynamic three-dimensional simulations. Flow patterns, mixing times, and mixing efficiencies were calculated, and the model supported with experimental results. The progress of mixing in the interdigital mixer was quantified by using the volume fractions of the organic and aqueous phases used during the emulsification–evaporation process. The developed model and methods were applied to determine the required time for achieving a complete mixing in each microreactor at different fluid flow conditions, temperatures, and mixing rates.

show abstract

Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate

Cited by 132 publications

References 23 publications

Dexamethasone Release from Within Engineered Cartilage as a Chondroprotective Strategy Against Interleukin-1α

Dexamethasone Release from Within Engineered Cartilage as a Chondroprotective Strategy Against Interleukin-1α

Treatment of Experimental Arthritis with Stealth-Type Polymeric Nanoparticles Encapsulating Betamethasone Phosphate

Continuous synthesis of drug-loaded nanoparticles using microchannel emulsification and numerical modeling: effect of passive mixing

Contact Info

Product

Resources

About